---
$id: https://graph.org.ai/products/commodity/51171925
$type: Product
source: UNSPSC
code: "51171925"
title: "Rebamipide"
class: "51171900"
classTitle: "Antiulcer and related gastrointestinal GI drugs"
family: "51170000"
familyTitle: "Drugs affecting the gastrointestinal system"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Rebamipide

**UNSPSC Code**: 51171925
**Class**: [Antiulcer and related gastrointestinal GI drugs](Antiulcer and related gastrointestinal GI drugs.mdx)
**Family**: [Drugs affecting the gastrointestinal system](../Drugs affecting the gastrointestinal system.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an anti-ulcer agent with the molecular formula C19H15ClN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LR583V32ZR, chemically known as 4-quinolinepropanoic acid, 1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-, (+-)- but generally known as rebamipide, which bears US NIH Compound Identifier 5042. European Medicines Agency schedules Rebamipide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10267MIG. The term REBAMIPIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). REBAMIPIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rebamipide under HS 29337900 and SITC 51561. As of Q4 2014, REBAMIPIDE remains the US FDA Preferred Term for this commodity. Rebamipide bears US NLM identifiers UMLS ID C0069562 and NCI Concept Code C29852. SMILES: CLC1CCC(C(=O)NC(CC2C3C([NH]C(=O)C2)CCCC3)C(=O)O)CC1.

